Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Authors: Strezova Ana , Diez-Domingo Javier , Al Shawafi Kamal , Tinoco Juan Carlos , Shi Meng , Pirrotta Paola , Mwakingwe-Omari Agnes ,   Zoster-049 Study Group, Adams Michael , Ahonen Anitta , Andrews Charles , Athan Eugene , BarbaGómez Jose-Fernando , Barbanti Piero , Barberan Elisabeth , Baty Alain , Bengtsson Niklas , Berger-Roscher Juergen , Blom Katarina Berndtsson , Beytout Jean , Boucher Loïc , Boutry Céline , Boye Alain , Brault François , Breger Laurie , Cuixart Carles Brotons , Caso Covadonga , Cerna Christine , Cheng Huey-Shinn , Cheong Hee Jin , Choo Eun Ju , Cunha Clóvis , Cunningham Anthony L , Curiac Dan , Daguzan Benoit , Dahmen Antje , Datta Susan , Desole Maria Giuseppina , Paolo Emmanuel Di , Dionne Marc , Dite Petr , Dutz Jan , Earl John , Eckermann Tamara , Ellison William , Eremenko Jurij , Esen Meral , Eto Takashi , Fabré Xavier Farrés , Farrington Cecil , Ferguson Murdo , Ferrand Pierre André , Finneran Matthew , Francyk David , Freedman Marshall , Freeman George , Freire Antônio Tarcísio , Gal Peter , Gauthier Jean-Sebastien , Gerlach Beatrice , Ghesquiere Wayne , Gorfinkel Iris , Grigat Christine , Grosskopf Josef , Hamann Monika , Hanrion Pascal , Hartley Paul , Hastie Andrew , Heaton Ken , Himpel-Boenninghoff Agnes , Horacek Thomas , Hui David Shu Cheong , Huong Yieng , Hwang Shinn-Jang , Icardi Giancarlo , Illies Gabriele , Irimajiri Junya , Jacob Wilson , Jambrecina Alen , Avelino-Silva Thiago Junqueira , Kalema George , Kim Hyo Youl , Klein Christiane , Kleinecke Uwe , Koenig Hans-Joachim , Kokko Satu , Kosina Pavel , Koski Susanna , Koskinen Pekka , Kropp Maximilian , Kuroki Rie , Laajalahti Outi , Lachance Pierre , Lee Jacob , Lee Jin-Soo , Levins Peter , Lipetz Robert , Liu Bo , Liu Chiu-Shong , Lundvall Martin , Magimaiseelan Luci , Manning Mary Beth , Markkula Jukka , Martin Frederick , Piera Pyrene Martínez , McNally Damien , McNeil Shelly , Migliorino Guglielmo , Moeckesch Beate , Morscher Stephan , Mueller Michael , Munir Abul Kashem , de Oliveira Cláudia Murta , Nakamura Kenjiro , Pérez Silvia Narejos , Naritomi Yuji , Nault Patrice , Neto José Luiz , López Concepción Núñez , Ogata Hiroaki , Olsson Åke , Paavola Pauliina , Park Dae Won , Patrick Janice , Pauksens Karlis , Vera Mercè Pérez , Peltonen Lauri , Plassmann Georg , Poder Airi , Poling Terry , Pretswell Carol , Purnell-Mullick Samir , Raad George , Redmond Michael , Remaud Philippe , Riffer Ernie , Robert Patrick , Badia Alex Rodríguez , de la Pinta Maria Luisa Rodríguez , Rombo Lars , Rosen Robert , Rozen Shari , Saillard Dominique , Salaun Bruno , Berglund Johan Sanmartin , Sauter Joachim , Schaefer Axel , Schenkenberger Isabelle , Schmidt Juergen , Schmitt Bernhard , Schubert Christian , Schuind Anne , Schwarz Tino , Seppa Ilkka , Sha Edmund Kwok Yiu , Shockey Gerald , Shoffner Sylvia , Sirnela-Rif Elina , Staniscia Tommaso , Sueki Hirohiko , Suzuki Shin , Taminau Denis , Tellier Guy , Riera Manuel Terns , Toma Azhar , Toursarkissian Nicole , Turner Mark , Ukkonen Benita , Morató Anna Vilella , Wachter Juergen , Webster Brian , Wilhelm Karl , Wilson Jonathan , Yeo Wilfred , Yu Chong-Jen , Zahaf Toufik , Zahharova Irina , Zerbini Cristiano 
Published: October 2022

Abstract
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.